TickerTalks
Browse all tickers →
TickerTalks›$SDGR
SDSDGR

Schrödinger, Inc.

$SDGR·$2.0B·Software - Application·Technology
$25.48+1.7%YTD+67.6%1Y+23.6%
Price updated 10h ago·X counts updated 4d ago
SDSDGR
$SDGRSchrödinger, Inc.
$25.48+1.72%157 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SDGR on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

157X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $SDGR's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-07-09

Schrödinger contributors highlight the AI-driven biotech sector regime in a synchronized bullish acceleration phase alongside ABCL, RXRX, and RLAY. Bulls describe SDGR as trading at 4x with the bio-plus-AI thesis potentially supporting a 30x multiple, framing it as a powerful multi-theme setup with enterprise software and biotech/pharma both catching bids. Tone leans constructive on the AI-driven drug discovery thesis.

Read what X is saying about $SDGR

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SDGR — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

AI-driven drug discovery is the trade, Schrödinger is the leveraged bet — up 68% YTD and still running.

Schrödinger is the AI-and-physics-based computational-chemistry platform used for drug discovery — a direct beneficiary of the 'AI biology' narrative that also drove MRNA, TWST, and others higher in 2026. The pivot from pure software-and-services to co-developed drug assets is the forward option.

  • The P&L is modest and losing money: Q2 revenue was flat at $59M YoY at a -83% operating margin and EPS of -$0.81, with the trailing EPS surprise swinging from +119% to -45% — these numbers reflect accounting swings on in-house drug programs, not steady-state operations.
  • The forward narrative has specific support: the 'company creation is now the real drug business' framing matches management's own disclosed strategy, and the AI-biology sector grouping alongside ABCL, RXRX, RLAY gives the stock a basket beta.

At 90% of its 52-week range and 90% above the 200-day with volume at 1.5x average, the setup is confirmed-breakout, not a coil. Nov 4 earnings is the test — a software-services revenue growth number plus co-developed program value disclosure is the trigger; another loss-widening quarter without named-program progress is the invalidation.

Agrees with X sentimentThe AI-biology sector-beta framing matches the chart and the sector rotation. The 4x-to-30x multiple expansion claim is aspirational — treat as upside optionality, not a modeled base case.

What to watch: Nov 4 Q3 earnings — software-services revenue growth, co-developed drug program updates, operating cash burn, and FY27 guide. Software growth plus named program progress is the trigger; widening loss without program news is the invalidation.

On the calendar: 2026-11-04 — Q3 earnings

event ahead 30dai biology

Read the AI verdict on $SDGR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides physics-based computational drug discovery software to pharma companies and runs an internal drug pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Software - Application sits in its cycle right now — and what that implies for $SDGR.

Software - Application · Technology

No material change from last week — Adobe Q3 lifted guidance with triple-digit AI-first ARR, validating the AI upsell bifurcation: vendors embedding AI agents into core workflows (NOW, CRM, SAP, WDAY, TEAM, ADBE) are re-accelerating whi.

What this means for $SDGR

Partial — Provides physics-based computational drug discovery software to pharma companies and runs an internal drug pipeline.; AI feature integration is the primary renewal variable in enterprise SaaS; execution on AI roadmap determines re-rating potential.

Top industry ETF

$IGViShares Expanded Tech-Software Sector ETF
+4.2%YTD
-3.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-34.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-64.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-30.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
55.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.08$-0.41+119.3%
Q1 2026May 5, 2026$-0.81$-0.56-44.6%
Q4 2025Feb 25, 2026$0.44$-0.13+438.5%
Q3 2025Nov 5, 2025$-0.45$-0.75+40.0%
Next earningsWed, Nov 4·consensus EPS $-0.67

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$58.6M-1.6%50.4%-83.3%$-0.81$-17.3M
Q4 FY25$87.2M-1.2%65.7%-19.7%$0.44$-16.1M
Q3 FY25$54.3M+53.9%51.6%-84.6%$-0.45$-62.4M
Q2 FY25$54.8M+15.7%47.8%-96.6%$-0.59$-52.5M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$242.7M$234.6M – $250.8M-$1.60-$1.66 – -$1.555
FY27$250.3M$242.0M – $258.6M-$1.42-$1.56 – -$1.265
FY28$280.2M$244.5M – $312.3M-$0.91-$1.64 – -$0.344
FY29$371.8M$347.6M – $396.5M-$0.01-$0.01 – -$0.012
FY30$406.5M$380.0M – $433.5M$0.40$0.37 – $0.432

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.64%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+55.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 57.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.625-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 17Karen AkinsanyaSee Remarks31.6K sh$928KSellJul 16Rachit JainCFO875 sh$14K
+ 11 other (9 awards · 1 exempt · 1 gift) in window

See when $SDGR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 298-K — Item 7.01: Press release / Reg FD
AI summary

Schrödinger, Inc. (SDGR) disclosed under Reg FD that Eli Lilly and Company has completed its acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrödinger. As a co-founder and equity holder in Ajax, Schrödinger is entitled to receive acquisition proceeds from the Lilly closing. The specific dollar amount flowing to Schrödinger is not disclosed in the excerpt. This is a meaningful cash catalyst — milestone or equity proceeds from a Lilly acquisition could be material relative to Schrödinger's balance sheet and cash position.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

________________________________________ Delaware 001-39206 95-4284541 reported departure or retirement of an officer: registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders of Schr. ________________________________________ Delaware 001-39206 95-4284541 disclosed voting results from its annual or special meeting. registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders of Schr...

8-KOfficer or director changeJun 88-K — Item 5.02: Officer or director change
AI summary

Schrödinger, Inc. (SDGR) formalized the separation of former Chief Commercial Officer Mannix Aklian on June 5, 2026, entering a transition, separation, and release agreement providing nine months of salary continuation, 12-month COBRA reimbursement, and additional benefits per his employment agreement and the company's Executive Severance Plan. The departure was previously disclosed; this filing confirms the financial terms. Routine executive separation with no new financial surprises.

8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Schrodinger, Inc. (SDGR) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in President. Individuals named in the filing include Floor New, Its Charter. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

+ 11 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistrybusinesswire.com·2d agoReviewing Claritev (NYSE:CTEV) and Schrodinger (NASDAQ:SDGR)defenseworld.net·4d agoAnalyzing Teladoc Health (NYSE:TDOC) & Schrodinger (NASDAQ:SDGR)defenseworld.net·4d agoSchrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100gurufocus.com·6d agoSchrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?zacks.com·10d ago

More in Software - Application

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NBIS$AI$STRK$ZETA$MSTR$BULL$UBER$APP
Voices on X · last 7 days

No standout posts about $SDGR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport